A New Generation of Drugs Could Lower Heart Attack Risk for Millions

A new class of drugs that silence the gene responsible for producing lipoprotein (a) – a hereditary, cholesterol‑like particle linked to heart attacks – is moving through late‑stage trials. Novartis expects its phase‑three readout within weeks, while Amgen and Eli Lilly have pipelines slated for results over the next one to two years, with Lilly also developing an oral formulation. Analysts estimate that, if the therapies prove effective, the Lp(a) market could generate as much as $25 billion a year, making it one of the biggest upcoming segments in cardiovascular medicine.

Regulators, however, will not approve the drugs solely on Lp(a) reduction. The FDA will demand clear evidence that lowering the particle translates into meaningful reductions in heart attacks and strokes, typically a 13‑20 percent relative risk drop to satisfy insurers and physicians. Past experience shows that promising biomarkers can fail to deliver clinical benefit, so trial designers are focusing on hard‑outcome endpoints. A successful outcome could reshape preventive cardiology, offering millions of genetically predisposed Americans a therapeutic option beyond diet, exercise, and statins, which can paradoxically raise Lp(a) levels.

The excitement around these therapies coincides with broader shifts in corporate strategy. Ford, for instance, is converting idle EV‑battery factories into a new energy‑storage subsidiary aimed at powering AI data centers, a move that has lifted its stock despite a slowdown in electric‑vehicle demand. Meanwhile, Lululemon’s board settlement with founder Chip Wilson and the ongoing U.S.–Iran economic negotiations illustrate how governance and geopolitical factors can influence market sentiment. Together, these developments underscore a landscape where breakthrough science, strategic repurposing, and macro‑economic dynamics intersect, offering investors multiple avenues for growth.